Medicine
Ondansetron 40 mg/20 mL injection
Ondansetron 40 mg/20 mL injection is a generic prescription medicine for intramuscular, intravenous use, made by 14 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20˚C to 25˚C (68˚F to 77˚F), excursions permitted to 15˚C to 30˚C…
Key facts
- Active ingredient (INN)
- Ondansetron
- Brand
- Sold under the generic name
- Strength
- 40 mg/20 mL
- Dosage form
- Injection
- Route
- Intramuscular, intravenous
- Packs
- 1 vial of 20 mL, 20 mL, 10 vials of 20 mL and 13 more
- Manufacturers
- Avet PharmaceuticalsIndiaAccord HealthcareIndiaEugiaIndiaGland PharmaIndiaWest-Ward PharmaceuticalsFosun PharmaFresenius KabiHealthFirstHikma PharmaceuticalsHospira
- Origin register
- US FDA, United States
- Storage
- Store at 20˚C to 25˚C (68˚F to 77˚F), excursions permitted to 15˚C to 30˚C (59˚F to 86˚F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A04AA01 Ondansetron
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 November 2006
- Identifiers
- RxCUI 283504, 1740467DailyMed set ID 35e0d160-813f-41d7-a382-d2cab6485d9c, b746d4db-43e6-4219-9e6b-f53e59581305, e0050959-c14c-41b6-9a92-fadc5f6feff3 +12NDC 16729-298, 23155-549, 63323-374 +12Application ANDA206846, ANDA090648, ANDA076974 +5
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 20 mL in 1 vial | 23155-549-31 | Avet PharmaceuticalsIndia | 15 June 2012 |
| 1 vial in 1 carton / 20 mL in 1 vial | 23155-550-31 | Avet PharmaceuticalsIndia | 9 November 2015 |
| 20 mL in 1 vial | 16729-298-05 | Accord HealthcareIndia | 20 October 2016 |
| 1 vial, multi-dose in 1 carton / 20 mL in 1 vial, multi-dose | 55150-126-20 | EugiaIndia | 21 December 2012 |
| 1 vial in 1 carton / 20 mL in 1 vial | 68083-114-01 | Gland PharmaIndia | 15 June 2012 |
| 1 vial in 1 carton / 20 mL in 1 vial | 72266-124-01 | Fosun Pharma | 2 April 2019 |
| 1 vial in 1 box / 20 mL in 1 vial | 63323-374-20 | Fresenius Kabi | 18 November 2009 |
| 20 mL in 1 vial, multi-dose | 0641-6286-01 | Hikma Pharmaceuticals | 26 December 2006 |
| 1 vial, multi-dose in 1 carton / 20 mL in 1 vial, multi-dose | 0409-4759-01 | Hospira | 7 November 2006 |
| 1 vial in 1 carton / 20 mL in 1 vial | 86211-115-01 | Jvet Pharmaceuticals | 23 March 2026 |
| 1 vial, multi-dose in 1 carton / 20 mL in 1 vial, multi-dose | 83270-161-01 | Onesource Specialty Pharma | 30 September 2023 |
| 20 mL in 1 vial, multi-dose | 0143-9890-01 | West-Ward Pharmaceuticals | 26 December 2006 |
| 10 vial, multi-dose in 1 carton / 20 mL in 1 vial, multi-dose | 0143-9890-10 | West-Ward Pharmaceuticals | 26 December 2006 |
| 20 mL in 1 vial | 51662-1377-1 | HealthFirst | 21 May 2020 |
| 1 vial, multi-dose in 1 bag / 20 mL in 1 vial, multi-dose | 71872-7107-1 | Medical Purchasing Solutions | 30 May 2018 |
| 1 vial, multi-dose in 1 carton / 20 mL in 1 vial, multi-dose | 85766-199-20 | Sportpharm | 14 April 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 4 January 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ondansetron
Clinical summary
Ondansetron is a serotonin-3 receptor antagonist. It is available as tablets, orally disintegrating tablets and injection for intramuscular and intravenous use. MedsAcross supplies Ondansetron for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OndansetronFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ondansetron prescribing information (Ascend Laboratories) · U.S. National Library of Medicine, DailyMed
Need Ondansetron 40 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.